High-purity reagents, expression systems, and rapid analysis platforms optimized for clinical research and commercial medical distribution.
Geneva stands at the epicenter of the European Life Sciences cluster (BioAlps), serving as an indispensable nexus for international organizations like the WHO, global purchasing agencies, and leading biotech research laboratories. Monoclonal antibodies (mAbs) represent one of the most dynamic sectors of modern medicine, transforming therapies for oncology, autoimmune conditions, and infectious diseases.
Our collaborative infrastructure bridges the gap between state-of-the-art biological development and rapid commercial distribution. By coupling high-density fermentation technologies with robust downstream chromatography, we supply the international market with premium-grade recombinant proteins and immunological diagnostic raw materials.
The therapeutic and diagnostic industries demand unprecedented batch consistency, robust scalability, and comprehensive documentation.
Modern pharmaceutical procurement departments encounter significant challenges regarding supply chain stability. The transition to single-use bioreactors has drastically reduced batch cross-contamination risks while decreasing facility turnaround times. Furthermore, the combination of Chinese cost-efficient manufacturing facilities with Swiss regulatory oversight gives buyers an unparalleled strategic advantage.
Hangzhou Jeci Biochem Technology Co., Ltd. serves as a crucial partner in this ecosystem. Headquartered in Hangzhou, Zhejiang Province, our firm specializes in the R&D, custom manufacturing, and global export of active pharmaceutical ingredients (APIs), key intermediates, and diagnostic formulations. Through intensive international trade relationships with India, Southeast Asia, South Korea, Japan, and the European market (specifically Geneva), we offer localized regulatory registration, technical consulting, and dependable logistics channels.
Our raw materials, recombinant proteins, and custom-synthesized active intermediates are globally integrated into clinical assays and therapeutic pathways, focusing on key industrial domains:
We boast advanced capabilities to assemble and produce bulk quantities of active intermediates under rigid quality control standards. Key strengths include:
Explore our full line of in-vitro rapid tests, antigens, and antibodies designed for immediate import and deployment.
Manufacturing clinical-grade monoclonal antibodies and highly specific diagnostic antigens necessitates a bulletproof quality management framework. At every step—from Chinese R&D processing centers to European distribution nodes in Geneva—we utilize state-of-the-art single-use bioreactors. This minimizes clean-in-place (CIP) complexity, removes the danger of inter-batch cross-contamination, and reduces ecological footprint, meeting the global pharma trend toward sustainable sourcing.
Furthermore, our consultation team provides comprehensive registration dossiers support (including DMF/CEP filings and regulatory submission templates for Chinese and European drug agencies). We facilitate technical transfers, handle customs clearance certificates, and ensure all rapid diagnostic products adhere strictly to the CE-IVDR and local Swissmedic regulatory updates.
Answers to critical questions regarding compliance, custom synthesis, international shipping, and scaling capabilities.
Gain access to validated chemical intermediates, active reagents, and clinical-grade monoclonal antibody lines backed by industry-leading quality management and reliable international logistics.
Send Inquiry Now
SJ medical
